Abstract
Polyglutamine (polyQ) diseases are inherited neurodegenerative disorders caused by proteins with expanded polyQ regions. Although the pathological mechanisms of these diseases have not yet been elucidated, the processes of protein misfolding and aggregation seem to be a direct cause of neurodegeneration. Detailed structural information on polyQ proteins is therefore essential in order to understand the mechanisms underlying pathogenesis and to design therapeutic strategies. In the past decade, several studies have investigated the structural properties of polyQ proteins and the molecular basis of aggregation and fibre formation. The results obtained in these studies are reviewed here.
Keywords: polyglutamine, aggregation, neurodegenerative diseases, structure, triplet expansion
Protein & Peptide Letters
Title: Polyglutamine and Neurodegeneration: Structural Aspects
Volume: 11 Issue: 3
Author(s): Laura Masino
Affiliation:
Keywords: polyglutamine, aggregation, neurodegenerative diseases, structure, triplet expansion
Abstract: Polyglutamine (polyQ) diseases are inherited neurodegenerative disorders caused by proteins with expanded polyQ regions. Although the pathological mechanisms of these diseases have not yet been elucidated, the processes of protein misfolding and aggregation seem to be a direct cause of neurodegeneration. Detailed structural information on polyQ proteins is therefore essential in order to understand the mechanisms underlying pathogenesis and to design therapeutic strategies. In the past decade, several studies have investigated the structural properties of polyQ proteins and the molecular basis of aggregation and fibre formation. The results obtained in these studies are reviewed here.
Export Options
About this article
Cite this article as:
Masino Laura, Polyglutamine and Neurodegeneration: Structural Aspects, Protein & Peptide Letters 2004; 11 (3) . https://dx.doi.org/10.2174/0929866043407147
DOI https://dx.doi.org/10.2174/0929866043407147 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Delayed Treatment with Nicotinamide Inhibits Brain Energy Depletion,Improves Cerebral Microperfusion, Reduces Brain Infarct Volume, but does not Alter Neurobehavioral Outcome Following Permanent Focal Cerebral Ischemia in Sprague Dawley Rats
Current Neurovascular Research Age-Related Changes in Motor Cortical Properties and Voluntary Activation of Skeletal Muscle
Current Aging Science Small Molecules that Promote Neurogenesis in vitro
Recent Patents on CNS Drug Discovery (Discontinued) Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging
Current Medicinal Chemistry Role of HIF-1 in Iron Regulation: Potential Therapeutic Strategy for Neurodegenerative Disorders
Current Molecular Medicine HspB5/αB-Crystallin: Properties and Current Progress in Neuropathy
Current Neurovascular Research Organotypic Hippocampal Slice Cultures for Studies of Brain Damage, Neuroprotection and Neurorepair
Current Drug Targets - CNS & Neurological Disorders The Metabotropic Glutamate Receptor System: G-Protein Mediated Pathways that Modulate Neuronal and Vascular Cellular Injury
Current Medicinal Chemistry - Central Nervous System Agents Amyloid β Accumulation Assessed with <sup>11</sup>C-Pittsburgh Compound B PET and Postmortem Neuropathology
Current Alzheimer Research Recent Advances in Obesity Pharmacotherapy
Current Clinical Pharmacology Selection of Potential Pharmacological Targets in ALS Based on Whole- Genome Expression Profiling
Current Medicinal Chemistry Recent Development of Multifunctional Agents as Potential Drug Candidates for the Treatment of Alzheimer’s Disease
Current Medicinal Chemistry Small Heat Shock Proteins: Recent Advances in Neuropathy
Current Neurovascular Research Exploring Structural and Physicochemical Profiles of Potential GSK-3β Inhibitors Using Structure- and Ligand-Based Modeling Studies
Combinatorial Chemistry & High Throughput Screening Role of Nicotinic Acetylcholine Receptors in Cardiovascular Physiology and Pathophysiology: Current Trends and Perspectives
Current Vascular Pharmacology Applications of iTRAQ and TMT Labeling Techniques to the Study of Neurodegenerative Diseases
Current Protein & Peptide Science Transporters at CNS Barrier Sites: Obstacles or Opportunities for Drug Delivery?
Current Pharmaceutical Design Inhibition of Human Serine Racemase, an Emerging Target for Medicinal Chemistry
Current Drug Targets Transgenic C. elegans as a Model in Alzheimers Research
Current Alzheimer Research Potential Therapeutic Effects of Oleuropein Aglycone in Alzheimer's Disease
Current Pharmaceutical Biotechnology